US Food and Drug Administration (USFDA) has concluded GMP follow-up inspection at Zydus Lifesciences’ oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad. The inspection was conducted from June 09 to June 18, 2025.
The inspection is closed with 2 observations and none of them were related to data integrity. The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
